A study of M710 a biosimilar candidate.
Phase of Trial: Phase I
Latest Information Update: 08 May 2017
At a glance
- Drugs M 710 (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Adverse reactions
- 08 May 2017 New trial record
- 02 May 2017 According to a Momenta Pharmaceuticals media release, company expects to initiate clinical trial in late 2017 or early 2018.